Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.

TitleBaseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.
Publication TypeJournal Article
Year of Publication2012
AuthorsAnthony DD, Conry SJ, Medvik K, Rani MRSandhya, Falck-Ytter Y, Blanton RE, Lederman MM, Rodriguez B, Landay AL, Sandberg JK
JournalJ Infect Dis
Volume206
Issue6
Pagination969-73
Date Published2012 Sep 15
ISSN1537-6613
KeywordsAdult, Antigens, CD14, Antigens, CD56, Antiviral Agents, Coinfection, Drug Therapy, Combination, Female, Genotype, Hepatitis C, HIV Infections, HIV-1, Humans, Interferon-alpha, Killer Cells, Natural, Male, Polyethylene Glycols, Receptors, IgG, Recombinant Proteins, Ribavirin
Abstract

Disease progression of human immunodeficiency virus type 1 (HIV-1) is associated with immune activation. Activation indices are higher during coinfection of hepatitis C virus (HCV) and HIV. The effect of immune activation on interferon α (IFN-α) therapy response is unknown. We evaluated soluble CD14 (sCD14) and natural killer (NK)-cell subsets at baseline, and during pegIFN-α2a/ribavirin therapy in HCV-HIV coinfection. The sCD14 level increased during therapy. Baseline sCD14 positively correlated with baseline HCV level and CD16(+)56(-) NK-cell frequency, and both sCD14 and CD16(+)56(-) NK cells correlated negatively with magnitude of HCV decline. IL28B genotype was associated with therapy response but not sCD14 or CD16(+)56(-) NK frequency. Markers of innate immune activation predict poor host response to IFN-α-based HCV therapy during HCV-HIV coinfection.

DOI10.1093/infdis/jis434
Alternate JournalJ. Infect. Dis.
PubMed ID22782948
PubMed Central IDPMC3501153
Grant ListAI 069501 / AI / NIAID NIH HHS / United States
AI 082151 / AI / NIAID NIH HHS / United States
AI 36219 / AI / NIAID NIH HHS / United States
AI 68634 / AI / NIAID NIH HHS / United States
AI 68636 / AI / NIAID NIH HHS / United States
AI-068636 / AI / NIAID NIH HHS / United States
R01 AI069195 / AI / NIAID NIH HHS / United States
R01 AI073963 / AI / NIAID NIH HHS / United States
R01 DK068361 / DK / NIDDK NIH HHS / United States